From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs
- 1 August 2017
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 45, 58-63
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Surrogate end points for overall survival in breast cancer trials: A reviewThe Breast, 2016
- Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancerAnnals of Oncology, 2016
- Approvals of drugs with uncertain benefit–risk profiles in EuropeEuropean Journal of Internal Medicine, 2015
- From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patientsClinical Pharmacology & Therapeutics, 2014
- Treating Patients as Persons: A Capabilities Approach to Support Delivery of Person-Centered CareThe American Journal of Bioethics, 2013
- Haematological anticancer drugs in Europe: any added value at the time of approval?European Journal of Clinical Pharmacology, 2007
- Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemiaBlood, 2006
- Patient-centredness: a conceptual framework and review of the empirical literatureSocial Science & Medicine, 2000
- Evidence based medicine: what it is and what it isn'tBMJ, 1996
- Assessing Patients' Capacities to Consent to TreatmentNew England Journal of Medicine, 1988